MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2026 International Congress

    Stage-Dependent Dysregulation of Peripheral TREM2, SOD1, and Neurofilament Light Chain Across the Parkinson’s Disease Continuum

    A. Calculli, D. Di Martino, R. Stiuso, H. Ferrari, C. Fazio, D. Comolli, P. Grillo, N. Polverino, M. Mancini, A. Pisani (Pavia, Italy)

    Objective: To evaluate plasma and PBMC biomarkers of neurodegeneration, neuroinflammation, microglial activation, and oxidative stress across clinically defined stages of Parkinson's disease (PD). Background: PD…
  • 2026 International Congress

    Phenotypic Overlap Between Essential Tremor and Dystonic Tremor: Diagnostic Features, Misclassification, and Clinical Implications :A Systematic Review

    S. Kakde, M. Kakde, S. Kakade (Aurangabad, India)

    Objective: To review evidence identifying clinical and neurophysiologic features that distinguish essential tremor from dystonic tremor and highlight patterns associated with diagnostic misclassification. Background: Distinguishing…
  • 2026 International Congress

    Admixture Mapping of the VA Million Veteran Program Cohort Implicates Novel Genetic Risk Loci for PD Driven by African and Native American Ancestry

    O. Lorenzo-Betancor, T. Leal, V. Borda, T. Thornton, T. O'Connor, I. Mata, C. Zabetian (Seattle, USA)

    Objective: To perform an admixture mapping analysis for Parkinson’s disease (PD) in the Veterans Affairs (VA) Million Veteran Program (MVP) cohort. Background: The genetics of…
  • 2026 International Congress

    Plasma Extracellular Vesicle Protein Biomarker Discovery for Monogenic and Sporadic Dystonia

    Z. Caffall, J. Jordan, A. Norain, L. Longyear, G. Aldykiewicz, T. Tran, A. Wagle-Shukla, N. Sharma, A. Nixon, E. Soderblom, N. Calakos (Durham, USA)

    Objective: To discover plasma biomarkers that differentiate people with dystonia from healthy controls (HC). Background: Blood-based biomarkers for dystonia could address several unmet clinical needs:…
  • 2026 International Congress

    Reduced Motor Unit Discharge Variability of Wrist Muscles 24 Hours After Closed-Loop Electrical Stimulation in Essential Tremor

    X. Yu, N. Kurukuti, H. Hassanlouei, G. Hoo, E. Roth, J. Pons (Jackson, USA)

    Objective: To investigate the acute and sustained effects of two peripheral electrical stimulation strategies on motor unit activity of wrist flexors and extensors in individuals…
  • 2026 International Congress

    Biomechanical Analysis of Gait Movement Disorders in Spinal Cord Injury and Its Implications for Rehabilitation Strategies

    M. Gupta, B. Garg (New Delhi, India)

    Objective: To systematically analyze the spatiotemporal, kinematic, and electromyographic gait movement disorders in patients with partial SCI for targeted rehabilitation strategies. Background: Spinal cord injury…
  • 2026 International Congress

    Pelizaeus Merzbacher like disease (PMLD): Neuroradiological Phenotyping

    K. Shah, M. Shah (Mumbai, India)

    Objective: To present an unusual case report. Background: Pelizaeus Merzbacher like disease (PMLD) is a hypomyelination disorder, usually manifesting in neonatal or an early infantile…
  • 2026 International Congress

    Post-COVID Movement Disorders: Clinical Spectrum and Mechanisms A Systematic Review

    S. Kakde, M. Kakde, S. Kakade (Aurangabad, India)

    Objective: To synthesize published evidence describing the clinical spectrum and proposed mechanisms of movement disorders occurring after infection with SARS-CoV-2. Background: Neurological complications have been…
  • 2026 International Congress

    Levels of IgA and IgG concentrations by stage of Parkinson’s disease

    S. Jumaniyozov, R. Matmurodov, H. Daminova, S. Inoyatova (Tashkent, Uzbekistan)

    Objective: To study of IgA and IgG levels cerebrospinal fluid of patients with different stages of PD. Background: In the clinical course of Parkinson's disease…
  • 2026 International Congress

    Efficacy and Safety of GLP-1 Receptor Agonists in Parkinson’s Disease: A Meta-Analysis Integrating the 96-Week Phase 3 Exenatide Trial Results

    K. Sarhan (Mansoura, Egypt)

    Objective: To evaluate the efficacy and safety of glucagon-like peptide-1 receptor agonists in patients with Parkinson’s disease (PD) through an updated systematic review and meta-analysis…
  • « Previous Page
  • 1
  • …
  • 198
  • 199
  • 200
  • 201
  • 202
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley